Investigating how a genetic variant affects heart function and blood flow in coronary microvascular disease.
Friend of GATA 2 (FOG2) S657G regulates ß1-adrenergic receptor and cardiac work to promote Coronary Microvascular Disease
['FUNDING_R03'] · UNIVERSITY OF PENNSYLVANIA · NIH-10950661
This study is looking at how a specific gene change might affect heart health by increasing stress on the heart, and it's for anyone interested in understanding more about coronary microvascular disease and finding better treatments.
Quick facts
| Phase | ['FUNDING_R03'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF PENNSYLVANIA (nih funded) |
| Locations | 1 site (PHILADELPHIA, UNITED STATES) |
| Trial ID | NIH-10950661 on ClinicalTrials.gov |
What this research studies
This research focuses on understanding the role of a specific genetic variant, FOG2S657G, in coronary microvascular disease (CMVD), which is a significant cause of heart-related issues. The study utilizes advanced models, including mouse and human stem cells, to explore how this variant increases the expression of the β1-adrenergic receptor, potentially leading to increased cardiac workload and oxygen demand. By examining the underlying mechanisms, the research aims to identify new insights into CMVD and pave the way for targeted therapies.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals with coronary microvascular disease or those at risk due to genetic factors.
Not a fit: Patients without coronary microvascular disease or those whose conditions are unrelated to the β1-adrenergic receptor may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatments for coronary microvascular disease, improving heart health and reducing the risk of serious cardiovascular events.
How similar studies have performed: Previous research has shown promising results in understanding genetic factors in heart disease, suggesting that this approach may yield valuable insights.
Where this research is happening
PHILADELPHIA, UNITED STATES
- UNIVERSITY OF PENNSYLVANIA — PHILADELPHIA, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: GUERRATY, MARIE A — UNIVERSITY OF PENNSYLVANIA
- Study coordinator: GUERRATY, MARIE A
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.